Factors associated with severity of orbitopathy in patients with Graves' disease

Nabi, Tauseef; Rafiq, Nadeema

doi:10.4103/tjo.tjo_10_20

Cited by 14 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of antibodies to thyroid-stimulating hormone receptors is statistically significantly higher in moderately severe endocrine ophthalmopathy 21.6 IU/l in comparison with mild endocrine ophthalmopathy 12.9 IU/l (p=0.001), which corresponds to the results of most researchers [6,10,12,13,14].…”

Section: Results Of the Research And Discussionsupporting

confidence: 83%

Clinical Significance of Antibodies to Thyrotropic Hormone Receptor as a Biomarker of Graves Disease Activity

Tsurkan¹,

Lushchik²,

Makeeva³

2022

EJNH

View full text Add to dashboard Cite

Objective: to study the clinical significance of antibodies to thyroid-stimulating hormone receptors as a biomarker of Graves' disease activity in patients in the Voronezh region. A retrospective study of 76 patients with Graves' disease treated at Voronezh Regional Clinical Hospital #1 from 2018 to 2021 was carried out. Qualitative and quantitative indicators were assessed: anamnestic data, features of the clinical picture, the results of laboratory and instrumental research methods at the first visit, in 6 and 12 months after antithyroid therapy. During the study, 3 groups were formed: group 1 -patients with Graves' disease -35 people, group 2 -patients with Graves' disease in combination with previously untreated endocrine ophthalmopathy -41 people, group 3 -control group of 15 people without thyroid disease. Our study found that male gender, smoking, free triiodothyronine levels, the severity of thyrotoxicosis and the presence of endocrine ophthalmopathy had a positive correlation with high levels of antibodies to thyroid-stimulating hormone receptors. Measurement of the level of antibodies to thyroid-stimulating hormone receptors in the blood in patients with Graves' disease helps to assess the course of Graves' disease complicated by endocrine ophthalmopathy and allows to determine the risk of activity and severity of endocrine ophthalmopathy. Determining the level of antibodies to thyroid-stimulating hormone receptors is recommended not only for rapid diagnosis, differential diagnosis, but also for monitoring the adequacy of treatment of patients with Graves' disease.

show abstract

Section: Results Of the Research And Discussionsupporting

confidence: 83%

Clinical Significance of Antibodies to Thyrotropic Hormone Receptor as a Biomarker of Graves Disease Activity

Tsurkan¹,

Lushchik²,

Makeeva³

2022

EJNH

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that when developing TED, the condition is more likely to advance into a severe and surgery-requiring form in men than in women. [18][19][20] This was also supported by our study, in which men were more likely to develop strabismus and undergo strabismus surgery than women.…”

Section: Discussionsupporting

confidence: 77%

Nationwide Incidence of Thyroid Eye Disease and Cumulative Incidence of Strabismus and Surgical Interventions in Denmark

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEThyroid eye disease (TED) is a serious condition that can cause proptosis and strabismus and, in rare cases, lead to blindness. Incidence data for TED and strabismus and surgical interventions after TED are sparce. OBJECTIVE To investigate the nationwide incidence of TED, strabismus, and surgical interventions associated with TED. DESIGN, SETTING, AND PARTICIPANTSA Danish nationwide registry-based cohort study between 2000, which marks the beginning of uniform coding for the decompression surgery nationwide, and 2018. The cohort consisted of a mean 4.3 million people aged 18 to 100 years with no prior TED diagnosis each year. Total observation time was 8.22 × 10 7 person-years (women, 4.18 × 10 7 person-years; men, 4.04 × 10 7 person-years). MAIN OUTCOME MEASURESThe annual numeric and age-standardized incidence of hospital-treated TED and cumulative incidence of strabismus, strabismus surgery, and orbital decompression surgery in patients with TED. The incidence was stratified by sex, thyroid diagnosis, and age.RESULTS A total of 4106 incident diagnoses of TED were identified during 19 years among 3344 women (81.4%) and 762 men (18.6%). The mean numeric annual nationwide incidence rate of TED was 5.0 per 100 000 person-years overall, 8.0 per 100 000 person-years in women, and 1.9 per 100 000 person-years in men, resulting in a 4:1 ratio of women to men with TED. The age-standardized incidence was similar. The mean (SD) age at onset was 51.3 (14.5) years. At the time of TED diagnosis, 611 patients (14.9%) were euthyroid, 477 (11.6%) were hypothyroid, and 3018 (73.5%) were hyperthyroid. In patients with TED who were euthyroid, the 4-year cumulative incidence was 41% for antithyroid medication and 13% for L-thyroxine. In patients with TED, the 4-year cumulative incidence for strabismus was 10%. The 4-year cumulative incidence of surgical interventions after TED was 8% for strabismus surgery and 5% for orbital decompression. At 4 years, strabismus surgery was more common in men (13.3%; 95% CI, 10.75-15.86) than in women (7.2%; 95% CI, 6.24-8.08), and the absolute difference was 6.1% (95% CI, 3.42-8.14; P < .001). CONCLUSIONS AND RELEVANCEThis study in Denmark provides nationwide empirical incidence of TED and strabismus and surgical interventions after TED that required inpatient or outpatient hospital treatment, and might be used for patient information and health care planning.

show abstract

“…The progression of Graves's ophthalmopathy varies among different patients. Males and smokers are associated to severe disease [16].…”

Section: Discussionmentioning

confidence: 99%

Graves’s Ophthalmopathy and Covid19: Choices and Cautions

Kheirjou

2021

JETR

View full text Add to dashboard Cite

Graves is a common autoimmune disease of the thyroid which results in many complications especially ophthalmopathy. Graves's ophthalmopathy is an inflammatory process that results in the enlargement of orbital soft tissues and vision problems. There are different approaches offered to the treatment of this problem. Recently the world has faced with covid 19 outbreak crises which can influence other disease and their treatment plans. We performed a review to determine the management of Graves's ophthalmopathy in regards to the SARS-CoV-2 pandemic. We concluded despite common reports of thyroid dysfunction in covid 19 diseases; it is not associated with an increased risk of COVID-19 related hospitalization or a worse outcome. We also recommend orbital radiotherapy and corticosteroid plus selenium supplement as the best choice for Graves ophthalmopathy.

show abstract

Factors associated with severity of orbitopathy in patients with Graves' disease

Cited by 14 publications

References 42 publications

Clinical Significance of Antibodies to Thyrotropic Hormone Receptor as a Biomarker of Graves Disease Activity

Clinical Significance of Antibodies to Thyrotropic Hormone Receptor as a Biomarker of Graves Disease Activity

Nationwide Incidence of Thyroid Eye Disease and Cumulative Incidence of Strabismus and Surgical Interventions in Denmark

Graves’s Ophthalmopathy and Covid19: Choices and Cautions

Contact Info

Product

Resources

About